JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Начало・Списък с акции・Cogent Biosciences Inc

Cogent Biosciences Inc

Затворен

36.84 1.91

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

36.53

Максимум

36.88

Ключови измерители
By Trading Economics
Приходи	-22M -102M
Служители	258
EBITDA	-30M -109M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+42.76% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	398M 6B
Предишно отваряне	34.93
Предишно затваряне	36.84

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

4.88 / 5.87 Подкрепа & съпротива

Cogent Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.04.2026 г., 19:19 ч. UTC

Придобивния, сливания и поглъщания

Intertek Group Rejects EQT's Revised Offer

24.04.2026 г., 23:37 ч. UTC

Придобивния, сливания и поглъщания

Scoring the Cook Era -- Barrons.com

24.04.2026 г., 20:51 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Financial Services Roundup: Market Talk

24.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

24.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 20:09 ч. UTC

Печалби

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24.04.2026 г., 19:48 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24.04.2026 г., 19:25 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 19:25 ч. UTC

Придобивния, сливания и поглъщания

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24.04.2026 г., 19:22 ч. UTC

Печалби

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24.04.2026 г., 19:06 ч. UTC

Печалби

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24.04.2026 г., 19:05 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24.04.2026 г., 18:30 ч. UTC

Придобивния, сливания и поглъщания

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24.04.2026 г., 18:28 ч. UTC

Придобивния, сливания и поглъщания

Intertek Rejects Revised EQT Offer

24.04.2026 г., 18:12 ч. UTC

Пазарно говорене

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24.04.2026 г., 18:06 ч. UTC

Пазарно говорене

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24.04.2026 г., 17:42 ч. UTC

Печалби

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24.04.2026 г., 17:28 ч. UTC

Печалби

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24.04.2026 г., 17:28 ч. UTC

Пазарно говорене

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24.04.2026 г., 17:12 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

24.04.2026 г., 17:11 ч. UTC

Пазарно говорене

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24.04.2026 г., 17:09 ч. UTC

Пазарно говорене

Печалби

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24.04.2026 г., 17:09 ч. UTC

Придобивния, сливания и поглъщания

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24.04.2026 г., 17:06 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24.04.2026 г., 16:51 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

24.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Значими събития в новините

Financial Services Roundup: Market Talk

24.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Auto & Transport Roundup: Market Talk

24.04.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Cogent Biosciences Inc Прогноза

Ценова цел

By TipRanks

42.76% нагоре

12-месечна прогноза

Среден 52.55 USD 42.76%

Висок 64 USD

Нисък 35 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Cogent Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Cogent Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

4.88 / 5.87Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.